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ABSTRACT
Disseminated fungal infection causes significant morbidity and mortality in children undergoing hematopoietic
stem cell transplantation (HSCT). The widespread use of prophylactic oral triazoles has limitations of poor
absorption, interindividual variability in metabolism, and hepatic toxicity. AmBisome (amphotericin B liposo-
mal complex) has a better safety profile than the parent drug amphotericin B and produces higher plasma and
tissue concentrations. We hypothesized that once-weekly high-dose AmBisome therapy could provide ade-
quate fungal prophylaxis for immunocompromised children undergoing HSCT. We performed a pharmaco-
kinetic pilot study to determine whether once-weekly high-dose AmBisome administration would result in
effective concentrations throughout the dosing interval. A total of 14 children (median age, 3 years, 1 month;
range, 4.5 months–9 years, 9 months) undergoing HSCT received once-weekly intravenous AmBisome
prophylaxis (10 mg/kg as a 2-hour infusion). Blood samples for pharmacokinetic measurements were drawn
around the first and the fourth weekly doses. The concentration of non–lipid-complexed amphotericin in
plasma was determined by a validated bioassay. Pharmacokinetic parameters after single doses and during
steady state were calculated using standard noncompartmental methods. AmBisome was well tolerated at this
dose. Complete pharmacokinetic profiles for weeks 1 and 4 were obtained in 12 patients. The half-life
calculated in this pediatric population was shorter on average than reported in adults (45 hours vs 152
hours). The volume of distribution correlated best with body weight (R2  .55), and clearance was best
predicted by initial serum creatinine level (R2  .19). Mean ( standard deviation) individual plasma
trough concentrations were 0.23 (0.13) mg/L after single doses and 0.47 (0.41) mg/L after multiple doses.
Mean steady-state area under the curve was higher at week 4 than after a single dose (P < .05). Single-dose
and steady-state pharmacokinetic profiles were similar in 8 patients, whereas in 4 patients the week 4
profile showed nonlinear elimination. However, plasma concentrations at 7 days (Cmin) were not signif-
icantly different after the first and fourth doses, suggesting no significant accumulation over the course of
therapy. Our data show measurable amphotericin B plasma concentrations 7 days after high-dose infusion
of AmBisome. This suggests that once-weekly dosing, as described in this study, may provide useful
protection against fungal infections.
© 2006 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
Disseminated fungal infection causes signiﬁcant
orbidity and mortality in immunocompromised
hildren. Among those at highest risk are children
ith leukemias (ie, acute myeloid leukemia [AML], d
B & M Telapsed acute lymphoblastic leukemia [ALL]), bone
arrow failure syndromes, or immunodeﬁciencies,
nd those undergoing allogeneic hematopoietic stem
ell transplantation (HSCT) [1-4]. Graft-versus-host
isease (GVHD) after allogeneic HSCT requires fur-
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2her immunosuppression and in turn increases the risk
f invasive fungal infections. The leading causes of
pportunistic fungal infections in these patients are
andida and Aspergillus species [1,5,6]. Most pediatric
eries of invasive aspergillosis report an overall sur-
ival rate of 15%-34% [1,7]. Very high mortality rates
re also reported for infections caused by other ﬁla-
entous fungi [8].
The life-threatening nature of this complication
arrants prophylaxis against fungal infections, which
s considered the standard of care for this group of
igh-risk patients. A number of options are available
or prophylaxis, but none has been found to be ideal.
rophylactic oral triazoles are limited by poor oral
bsorption, interindividual variation in metabolism,
nd hepatic toxicity, leading to reports of break-
hrough infections [9]. Conventional amphotericin B
as been used prophylactically [10], but is associated
ith infusional toxicity, long-term nephrotoxic side
ffects [11], and need for frequent infusions. AmBi-
ome is a liposomal formulation consisting of ampho-
ericin B in small, unilamellar vesicles. AmBisome has
unique composition, containing cholesterol and
harged phospholipids, which stabilize the liposomes
nd prolong their residence in plasma. AmBisome
auses fewer infusional reactions [12-14] and produces
igher plasma and tissue concentrations compared
ith the parent drug amphotericin B [15-19]. The
ower toxicity of the liposomal formulation allows the
dministration of much higher doses. Prophylaxis
ith AmBisome has been investigated at doses of 1-2
g/kg/day in high-risk patients in several studies [20-
2]. Widespread and long-term use is limited by the
eed for frequent intravenous administration, how-
ver. An alternative approach to prophylaxis is once-
eekly high-dose AmBisome therapy. This strategy is
imple and convenient for patients, helps ensure com-
able 1. Patient Demographics
Patient # Age We
1 9 months
2 3 years, 2 months
3 9 years, 9 months
4 3 years, 9 months
5 8 years, 2 months
6 1 year, 4 months
7 2 years, 2 months
8 3 years
9 4.5 months
10 4 years, 5 months
11 11 months
12 1 year, 5 months
13 6 years, 8 months
14 4 years, 5 months
Median (range) 3 years, 1 month (4.5
months-9 years, 9 months)
13.8
CID indicates severe combined immunodeﬁciency; DBA, Diamo
phagocytic lymphohistiocytosis; WAS, Wiskott-Aldrich syndrome.
36liance in young children in whom frequent oral med-
cation doses can be a challenge, and has the potential
o generate high tissue concentrations of amphoteri-
in B.
To date, no pharmacokinetic data for AmBisome
n children have been reported in the literature. To
nvestigate the potential of weekly prophylactic ad-
inistration, we performed a pilot pharmacokinetic
tudy of once-weekly high-dose (10 mg/kg) AmBisome
herapy in pediatric patients undergoing HSCT.
ETHODS
This study was a prospective open-label single-
enter observational clinical trial aimed at studying the
harmacokinetics of once-weekly high-dose AmBisome
herapy in children. Patients receiving HSCT in whom
ntifungal prophylaxis was clinically indicated were
ligible for the study. A total of 14 children with
arious hematologic disorders, metabolic disorders,
nd immunodeﬁciency syndromes undergoing HSCT
ere enrolled (Table 1). The study included only
hildren age 10 years, because the goal of our study
as to evaluate the pharmacokinetics of AmBisome in
mall children. The median age was 3 years, 1 month
range, 4.5 months–9 years, 9 months), and the male-
o-female ratio was 2:1. None of the patients had a
istory of previous fungal infection.
The study design was approved by the Cincinnati
hildren’s Hospital Medical Center’s Institutional
eview Board (IRB), and consent was obtained from
ach child’s parents before the child was enrolled in
he study.
AmBisome (Fujisawa Healthcare, Deerﬁeld, IL), a
yophilized liposomal preparation of amphotericin B,
as reconstituted according to the manufacturer’s in-
) Sex Diagnosis
Male SCID
Male DBA, ALL, SCID
Female Fanconi’s anemia
Male Neuroblastoma
Female Fanconi’s anemia
Male HLH
Female Amegakaryocytic thrombocytopenia
Female Neuroblastoma
Male SCID
Male Sideroblastic anemia
Male WAS
Male Congenital erythropoietic porphyria
Female Niemann-Pick disease
Male Glanzmann’s thrombasthenia
.7) 5/9 (F/M)
ckfan anemia; ALL, acute lymphoblastic leukemia; HLH, hemo-ight (kg
9.0
13.0
44.7
12.4
20.6
19.9
13.5
14.1
5.8
22.0
9.1
13.0
22.0
18.7
(5.8-44
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Weekly AmBisome Antifungal Prophylaxis
Btructions to give a 4-mg/mL solution. Drug dilutions
or injection were prepared as needed with 5% dex-
rose. All patients received once-weekly intravenous
mBisome prophylaxis at a dose of 10 mg/kg.
harmacokinetic Sampling
Serial blood samples were drawn around the ﬁrst and
he fourth weekly doses. Venous blood samples (2.0 mL)
ere obtained from an indwelling catheter immediately
efore AmBisome administration (ie, time 0) and then
t 0.5, 1, 2, 2.5, 3, 4, 6, 24, 60, 96, 120, 144, and 168
ours after administration.
mphotericin Assay
The concentration of non–lipid-complexed am-
hotericin in plasma was determined by validated bio-
ssay with Paecilomyces variotii as an indicator organism
23] in the laboratory of Dr. David Stevens, Division
f Infectious Diseases, Santa Clara Valley Medical
enter, San Jose, California. The lower limit of de-
ection by this assay was 0.03 g/mL. The intraday
nd interday coefﬁcients of variation were 10% and
anged from 2.3% to 9.6%.
harmacokinetic Analysis
Pharmacokinetic analyses of single-dose and steady-
tate data were conducted using standard noncompart-
ental methods (WinNonlin Professional version 4.0;
harsight, Mountain View, CA). Individual plasma
rough concentrations were determined by visual in-
pection of the plasma concentration–time proﬁles.
he apparent terminal elimination rate constant (z)
or AmBisome was estimated for each subject by non-
inear regression analysis. The area under the plasma
oncentration–time curve (AUC0-; AUC0-) was de-
ermined using the linear trapezoidal method. Total
ody clearance (CL), volume of distribution (Vz), and
erminal half-life (T½) were calculated using standard
quations.
tatistical Analysis
Data are presented as mean  standard deviation
SD). The 2-tailed Student t-test for paired data was
sed to compare pharmacokinetic estimates after sin-
le and multiple doses. A P value .05 was considered
igniﬁcant. Associations between pharmacokinetic
easures and patient data (eg, age, height [Ht], body
eight [Wt], body surface area [BSA], body mass in-
ex) were evaluated using Spearman’s correlation co-
fﬁcient at the .05 signiﬁcance level. Statistical analy-
es were performed using SPSS version 11.5 for
indows (SPSS, Chicago, IL).
ESULTS
Fourteen patients completed week 1, and 12 com-
leted both the week 1 and week 4 pharmacokinetic g
B & M Ttudies. One participant did not complete the week 4
tudy because of problems with venous access, and
nother developed infusion toxicity (fever, rash, and
eg cramps) requiring withholding of the week 4 dose.
mBisome was well tolerated at this dose in all of the
ther subjects. The mean change in serum creatinine
evel between week 1 and week 4 was 0.07 mg/dL
P  .12). None of the patients developed hypokale-
ia, hypomagnesemia, or increased alkaline phospha-
ase or tranaminase levels.
The mean concentration-time proﬁles of nonlipo-
omal amphotericin B in plasma after the ﬁrst dose
week 1) and during steady state (week 4) are shown in
ig. 1. As a result of measuring nonliposomal ampho-
ericin B as opposed to total liposomal content, the
nitial drug concentrations did not increase in a linear
ashion with dose and continued to rise after the end
f AmBisome infusion in some patients, due to release
f active amphotericin from the liposomal vehicle.
eak concentrations were observed between 1 and 6
ours after the start of the AmBisome infusion and
anged from 2.1 to 3.4 mg/mL after week 1 and from
.6 to 3.8 mg/L at week 4. The elimination half-life
anged from 28.5 to 107.5 hours, shorter than that
reviously described in adults [24].
Pharmacokinetic parameter estimates after a sin-
le dose (week 1) and during steady state (week 4) for
he 12 patients who completed both parts of the study
re summarized in Table 2. Parameter estimates for
he 2 patients who completed only the ﬁrst week of
he study were similar. Comparing the parameters
fter week 1 and week 4 revealed no statistically sig-
iﬁcant differences except for the AUC (Table 2). The
UC, as determined by the trapezoidal rule, ranged
rom 79 to 275 mg · h/L in week 1 and 105 to 462
g · h/L in week 4 (P  .03).
Plasma levels at 7 days (Cmin) were not signiﬁ-
antly different after the ﬁrst and fourth doses, sug-
igure 1. Pharmacokinetic proﬁles for week 1 and week 4 (mean 
D): Mean concentration–time proﬁles of nonliposomal amphoter-
cine B in pediatric HSCT patients. Mean data points (SD) are
raphically connected for each course of therapy in week 1 and week 4.
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2esting no accumulation over the course of therapy.
he half-life measured in our study group was shorter
han that reported in adults (43-55 hours vs 152 hours)
24]. The volume of distribution (Vz) and clearance
CL) values in our group were higher than those
eported in adults and correlated positively with body
eight Vz  CL (R2  .55 for Vz; R2  .19 for CL)
Figs. 2 and 3). The volume of distribution was sig-
iﬁcantly correlated with Wt, Ht, and BSA for both
eek 1 and week 4. There was a trend toward a
orrelation between Wt and clearance (week 1) that
id not achieve statistical signiﬁcance (Table 3).
Only one patient (patient 3) developed evidence of
ungal infection. This child had a single pulmonary
odule removed, and even though all cultures re-
ained negative, pathological examination suggested
ungal infection. The patient was treated with empiric
ntifungal therapy and remains well 9 months post-
ransplantation.
able 2. Mean (SD) Pharmacokinetic Parameter Estimates after
eek 1 and Week 4 Therapy in 12 Patients
Parameters
(unit)
Week 1
(n  12)
Week 4
(n  12)
P
Value
max (mg/L) 2.71 (0.47) 3.02 (0.39) NS
max (h) 2.52 (1.42) 2.33 (0.99) NS
rough (mg/L) 0.23 (0.13) 0.47 (0.41) NS
½ (h) 43.42 (14.11) 54.99 (24.32) NS
UC0- (hr*mg/L) 156.21 (69.73) 255.29 (133.74) .03
z (L/kg) 4.19 (1.14) 4.24 (2.85) NS
L (L/hr/kg) 0.0744 (0.0338) 0.0593 (0.0407) NS
max indicates peak plasma concentration; Tmax, time to peak
plasma concentration; t½, elimination half-life; AUC0-, area
under the plasma concentration-time curve extrapolated to in-
ﬁnity; Vz, volume of distribution; CL, total body clearance; NS,
not signiﬁcant.
igure 2. Correlation between body weight and volume of distri-
ution (Vz): Correlation plot of individual estimates for volume of
istribution (in L) versus body weight (WT in Kg). The solid line
s the line of best ﬁt for the data (R2  .55). The dashed linecepresents the 95% conﬁdence intervals.
38ISCUSSION
In this study we evaluated the pharmacokinetics of
igh-dose AmBisome given once weekly to young
hildren (age 10 years). Our interest in weekly ad-
inistration of AmBisome came from 2 sources. First,
nimal studies have suggested that this dosing sched-
le may be effective. Garcia et al [25] used a mouse
odel of Candida albicans and Histoplasma capsulatum
nfection [25] to demonstrate the efﬁcacy of a single
rophylactic dose of AmBisome (1-20 mg/kg) given 7
ays before challenge. These and recent data using
nvasive Aspergillosis as a model suggest that biologi-
ally relevant blood and tissue levels of drug may be
resent 7 days after administration of a single dose of
mBisome [26]. The second impetus for the study was
he clinical challenge of administering long-term oral
ntifungal prophylaxis (eg, with azoles) to small chil-
ren. Small children may not accept oral administra-
ion, and hepatic toxicity is common. Alternative ther-
py with an echinocandin (eg, caspofungin) requires
aily intravenous administration. We reasoned that if
eekly dosing provided reasonable plasma levels of
mBisome, then this would provide a simple pro-
hylaxis regimen that could be administered for
ong periods on an outpatient basis. In addition, if a
eekly schedule was feasible, then the strategy
ould be applied to other populations needing long-
erm prophylaxis, such as children with bone mar-
ow failure syndromes, AML or high-risk ALL, and
mmune deﬁciencies.
Our study has demonstrated a consistent pharma-
okinetic proﬁle for AmBisome administered at this
ose, with nonliposomal amphotericin plasma levels
etectable on the seventh day before redosing and no
ccumulation found with repeated dosing. Previous in
itro time-kill and post-antifungal effect (PAFE) stud-
es with amphotericin B have demonstrated concentra-
igure 3. Correlation between body weight and clearance (CL):
orrelation plot of individual estimates for clearance (in L/h) versus
ody weight (WT in Kg). The solid line is the line of best ﬁt for the
ata (R2 .19, not signiﬁcant). The dashed line represents the 95%
onﬁdence intervals.
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Weekly AmBisome Antifungal Prophylaxis
Bion-dependent activity and signiﬁcant PAFE against a
ariety of yeasts [27]. These and other studies have dem-
nstrated that the peak serum level/minimum inhibitory
oncentration (MIC) ratio was the pharmacokinetic and
harmacodynamic parameter that most strongly corre-
ated with the efﬁcacy of amphotericin B. In addition,
erum drug concentrations have been shown to be a
elatively good surrogate of tissue concentrations. The
oncentrations of nonliposomal amphotericin B at 7
ays (the end of interval in this study) are around the
ICs for susceptible strains (Candida, 0.25-1 mg/L;
spergillus, 0.5-2 mg/L) [28].
A limitation of our study was the absence of mea-
ured tissue AmBisome concentrations. Most of the
linical beneﬁt of AmBisome likely requires tissue
ispersion of the drug. A recent study found that a
nce-weekly 15-mg/kg AmBisome dose given to adult
atients undergoing HSCT achieved high, sustained
issue concentrations, similar to those achieved with
onventional (1 mg/kg) daily dosing. The mean tissue-
o-plasma concentration ratio of AmBisome on day 7
as 16.3, suggesting markedly higher tissue drug lev-
ls compared with measured plasma levels [29]. These
ata indicate that in adults, AmBisome can be given
afely in high doses and support our hypothesis that
nce-weekly AmBisome dosing may provide effective
ntifungal prophylaxis in small children.
Data collected in adults receiving therapy for proven
r likely fungal infections have demonstrated that Am-
isome doses as high as 15 mg/kg are well tolerated [30].
maximum tolerated dose (MTD) was not reached in
his dose escalation study, and the major toxicities of
nfusion reactions and renal impairment did not appear
o be dose-related. Of interest, this study demonstrated
onlinear pharmacokinetics of AmBisome at doses 10
g/kg, with no further increase in Cmax or AUC with a
ose of 12.5 or 15 mg/kg. These data suggest the uptake
f AmBisome in the reticuloendothelial system, the ma-
or pathway for extraction of AmBisome from the
lasma, with accumulation of the drug in tissues. This
nding has the potential to offer protection to the liver
nd spleen, and possibly the lungs at higher doses, sites
articularly vulnerable to mold or yeast infection.
able 3. Associations Between Pharmacokinetic Measures and Patient D
Week 1
Vz (L) CL (L/h)
ge 0.546* 0.383
eight 0.740† 0.443
eight 0.692† 0.543*
SA 0.679† 0.437
erum creatinine 0.747† 0.612*
z indicates volume of distribution; CL, total body clearance; AUC
Correlation is signiﬁcant at the 0.05 level (2-tailed).
Correlation is signiﬁcant at the 0.01 level (2-tailed).We selected a dose of 10 mg/kg for our study due to
B & M The nonlinear pharmacokinetics of AmBisome at higher
oses as well as data indicating that this dose is below the
TD of AmBisome, at least in adults, in whom doses of
5 mg/kg/day did not reach MTD. In our study, 10
g/kg dosing was well tolerated, with a single case of
nfusion toxicity and no renal, liver, or other toxicities,
uggesting that this is a safe strategy for long-term use.
eekly AmBisome therapy carries a signiﬁcant cost,
igher than oral therapy but (in most hospitals) is less
xpensive than daily echinocandin therapy. Weekly Am-
isome therapy offers an option for long-term prophy-
axis in children unable to tolerate oral azole therapy.
Liposomal amphotericin B has been shown to have a
ong terminal half-life (approximately 152 hours) in nor-
al adults [24]. In our population of young children, we
ound a signiﬁcantly shorter half-life for nonliposomal
mphotericin B. In addition, the volume of distribution
as associated with weight, suggesting some pharmaco-
inetic differences between small children and adults.
hen interpreting these data, it is important to note that
n contrast to many previous reports that describe the
harmacokinetics of total amphotericin B (the sum of
iposomal, plasma protein–bound, and free or unbound
rug), we have measured the pharmacokinetics of the
ctive portion of the drug or non–lipid-complexed am-
hotericin, making it difﬁcult to directly compare our
esults with earlier pharmacokinetic results. Although
ur study was not designed to prove the efﬁcacy of this
pproach, the data provide support for a clinical study of
his prophylaxis strategy.
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